BIM
AIMT

BlackRock Investment Management’s Aimmune Therapeutics AIMT Stock Holding History

BlackRock Investment Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$1.96M Sell
95,666
-129
-0.1% -$2.64K ﹤0.01% 2231
2016
Q3 		$1.44M Sell
95,795
-246
-0.3% -$3.32K ﹤0.01% 2426
2016
Q2 		$1.04M Buy
96,041
+57,463
+149% +$781K ﹤0.01% 2611
2016
Q1 		$523K Buy
38,578
+988
+3% +$15.4K ﹤0.01% 2885
2015
Q4 		$694K Buy
37,590
+489
+1% +$9.05K ﹤0.01% 2832
2015
Q3 		$939K Buy
+37,101
New +$867K ﹤0.01% 2649

Other funds holding AIMT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
TG
TLP Group Evanston, Illinois $6.61M AUM 12.46% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

BlackRock Investment Management's AIMT Position: Q4 2016 in Review

BlackRock Investment Management reduced its Aimmune Therapeutics (AIMT) stake by 0.13% in Q4 2016, selling an estimated $2.64K and leaving 95,666 shares worth $1.96M. The position accounts for ﹤0.01% of the portfolio, ranked #2231.

BlackRock Investment Management first reported a position in AIMT in Q3 2015 and has held it in 6 quarters since. 92 funds tracked by Wall St. Rank hold AIMT as of Q4 2016.

  • BlackRock Investment Management held 95,666 shares of Aimmune Therapeutics worth $1.96M as of Q4 2016.
  • BlackRock Investment Management sold 129 Aimmune Therapeutics shares in Q4 2016, an estimated $2.64K.
  • Aimmune Therapeutics made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2231 holding.
  • BlackRock Investment Management first reported a position in Aimmune Therapeutics in Q3 2015 and has held it in 6 quarters since.
  • 92 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.